(Q33411577)

26 July 2017

title

Successful treatment of DEAP-HUS with eculizumab (English)

1 reference

26 July 2017

Fred G Pluthero

3

0 references

Damien G. Noone

1

object named as

Damien Noone

1 reference

26 July 2017

Aoife Waters

2

1 reference

26 July 2017

Denis F Geary

4

1 reference

26 July 2017

Michael Kirschfink

5

1 reference

26 July 2017

Peter F Zipfel

6

1 reference

26 July 2017

Christoph Licht

7

1 reference

26 July 2017

publication date

20 November 2013

1 reference

26 July 2017

1 reference

26 July 2017

volume

29

1 reference

26 July 2017

issue

5

1 reference

26 July 2017

page(s)

841-851

1 reference

Atypical hemolytic-uremic syndrome

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Complement and the atypical hemolytic uremic syndrome in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Anti-Factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Successful treatment with rituximab for acute refractory thrombotic thrombocytopenic purpura related to acquired ADAMTS13 deficiency: a pediatric report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Terminal complement complex (C5b-9) in children with recurrent hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor h and factor h-related protein 1 to pentraxin 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Plasmatherapy in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

The autoimmune disease DEAP-hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

The development of atypical hemolytic uremic syndrome depends on complement C5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Eculizumab for congenital atypical hemolytic-uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Pathogenic significance and diagnostic value of lupus autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Comparison between multiplex assays for autoantibody detection in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Role of antineutrophil cytoplasmic antibodies and glomerular basement membrane antibodies in the diagnosis and monitoring of systemic vasculitides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Anti-phospholipase A₂ receptor antibodies correlate with clinical status in idiopathic membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Atypical HUS: time to take stock of current guidelines and outcome measures?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

Eculizumab for Atypical Hemolytic–Uremic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2654-X

21 January 2018

1 reference

12 December 2020

Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysis

1 reference

12 December 2020

Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome

1 reference

12 December 2020

Therapeutic plasma exchange in renal diseases

1 reference

12 December 2020

Eculizumab (Alexion).

1 reference

12 December 2020

Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus

1 reference

12 December 2020

10.1007/S00467-013-2654-X

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1026622116

0 references

1 reference